Monkeypox Virus Real Time PCR Kit (RUO)

Background
This systematic review traces monkeypox from its 1970 identification to the 2022 global outbreak, declared a public health emergency. It synthesizes transmission routes, clinical signs, risk groups, and diagnostic approaches, including RT-PCR and virus-specific kits. It discusses the lower mutation capacity of poxviruses, differences between West and Central African clades, and the roles of smallpox vaccines (ACAM2000, JYNNEOS) and antivirals such as tecovirimat. The authors emphasize early detection, infection control, destigmatization, and international cooperation, especially in resource-limited African regions.
Key Findings
The review finds that monkeypox re-emerged in May 2022, reaching 78,000 cases by November, predominantly among men (98%, mean age 41). Transmission occurs via animal contact, respiratory droplets, bodily fluids, skin lesions, and close physical/sexual contact; mother-to-fetus transmission is possible. The West African clade is less virulent than the Central African clade. Clinical features include fever, lymphadenopathy, and a rash progressing from macules to pustules; complications include secondary infections, bronchopneumonia, encephalitis, and corneal infection. Mortality is 1-10%, higher in children (~15%) and HIV-positive individuals. Diagnosis relies on RT-PCR, with kits from Bio Perfectus, Creative Biogene, Altona, and Runmei for confirmation. Prevention includes ACAM2000 and JYNNEOS vaccines; tecovirimat is the preferred antiviral, targeting VP37. The authors stress early detection, risk-group monitoring, and destigmatization.
Contribution
Creative Biogene Biotechnology is cited as one of the commercial suppliers of monkeypox virus-specific diagnostic kits, alongside Bio Perfectus and others, after broader orthopoxvirus detection. The article does not report any direct research, experimental, or authorship contribution by Creative Biogene; its role is limited to being a referenced diagnostic product source.

Background
This literature review examines cardiovascular concerns associated with smallpox vaccines used for monkeypox immunization during the 2022 global outbreak. It summarizes evidence on ACAM2000, JYNNEOS, and modified vaccinia Ankara, reporting that ACAM2000 is linked to myocarditis, pericarditis, dilated cardiomyopathy, and heart failure, whereas JYNNEOS/MVA cause mostly minor events such as tachycardia, palpitations, and ECG changes. The authors emphasize risk-benefit assessment before mass vaccination, cardiac workup for vaccinated patients with chest pain, and further research to clarify incidence and mechanisms.
Key Findings
Key findings: The review identified three smallpox vaccines used for monkeypox—ACAM2000, JYNNEOS, and modified vaccinia Ankara (MVA). ACAM2000 was associated with major cardiovascular adverse events, including myocarditis, pericarditis, dilated cardiomyopathy, and heart failure. Reported myo/pericarditis incidence was approximately 5.7 per 1,000 healthy primary ACAM2000 recipients, with higher rates after first vaccination; subclinical myocarditis was more common than clinical disease and troponin T elevation occurred. JYNNEOS and MVA caused mostly minor events such as tachycardia, palpitations, T-wave inversion, and ST elevation; among 2,126 JYNNEOS recipients, 10 reported chest pain or palpitations. The authors recommend risk-benefit assessment before mass immunization, monitoring vaccinated patients with chest pain, ECG and cardiac biomarker testing, VAERS reporting, and further research on incidence and mechanisms.
Contribution
Creative Biogene is cited only for its Monkeypox Virus Real Time PCR Kit, referenced as a commercial diagnostic resource for laboratory confirmation of monkeypox. The company did not contribute to the study design, literature search, data analysis, or manuscript preparation. Its role is limited to providing a PCR detection product mentioned in the reference list.